<p><strong>纽约，纽约 / ACCESS Newswire /2025 年 5 月 18 日/</strong> 如果您在 <strong>西氏医药服务公司</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
<p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
<p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
<p><strong>诉讼：</strong> 针对西氏医药服务公司提起了一项集体诉讼，旨在追回在 2023 年 2 月 16 日至 2025 年 2 月 12 日期间因涉嫌证券欺诈而受到不利影响的股东的损失。</p>
<p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(a) 尽管声称对客户需求有强烈的可见性，并将逆风归因于暂时的 COVID 相关产品去库存，西氏实际上在其高利润的 HVP 产品组合中经历了显著且持续的去库存；(b) 西氏的 SmartDose 设备，原本被定位为高利润增长产品，由于运营效率低下，对公司的利润率造成了高度稀释；(c) 这些利润压力带来了昂贵的重组活动风险，包括公司退出与长期客户的连续血糖监测合同；(d) 因此，被告对公司业务、运营和前景的积极陈述在实质上是虚假和/或误导的，或缺乏合理依据。</p>
<p><strong>接下来怎么办？</strong> 如果您在相关时间段内在西氏医药服务公司的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中建立了成功记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往结果不保证类似结果。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>纽约，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>电话：(212) 363-7500</p>
<p>传真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

西氏医药服务

<p>针对西氏医药服务公司（West Pharmaceutical Services, Inc.，股票代码：WST）提起了一项集体诉讼，指控其在 2023 年 2 月 16 日至 2025 年 2 月 12 日期间对股东进行证券欺诈。诉状声称，该公司就其财务健康状况和运营效率做出了虚假陈述，特别是关于其高利润产品和利润率的情况。在此期间遭受损失的股东被鼓励联系 Levi & Korsinsky LLP 以寻求潜在的赔偿选项</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / May 18, 2025 /</strong> If you suffered a loss on your <strong>West Pharmaceutical Services, Inc.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>纽约，纽约 / ACCESS Newswire /2025 年 5 月 18 日/</strong> 如果您在 <strong>西氏医药服务公司</strong> 的投资中遭受损失，并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：</p>
</div><p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通过电子邮件联系 Joseph E. Levi 律师，邮箱为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against West Pharmaceutical Services, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025.</p>
<div class="lb-trans"><p><strong>诉讼：</strong> 针对西氏医药服务公司提起了一项集体诉讼，旨在追回在 2023 年 2 月 16 日至 2025 年 2 月 12 日期间因涉嫌证券欺诈而受到不利影响的股东的损失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with longstanding customers; and (d) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(a) 尽管声称对客户需求有强烈的可见性，并将逆风归因于暂时的 COVID 相关产品去库存，西氏实际上在其高利润的 HVP 产品组合中经历了显著且持续的去库存；(b) 西氏的 SmartDose 设备，原本被定位为高利润增长产品，由于运营效率低下，对公司的利润率造成了高度稀释；(c) 这些利润压力带来了昂贵的重组活动风险，包括公司退出与长期客户的连续血糖监测合同；(d) 因此，被告对公司业务、运营和前景的积极陈述在实质上是虚假和/或误导的，或缺乏合理依据。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in West Pharmaceutical Services, Inc. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下来怎么办？</strong> 如果您在相关时间段内在西氏医药服务公司的股票中遭受损失——即使您仍持有股份——请访问 https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=149110&amp;wire=1&amp;utm_campaign=29 了解您寻求赔偿的权利。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去 20 年中，Levi &amp; Korsinsky LLP 已建立为一家全国知名的证券诉讼公司，为受害股东争取了数亿美元，并在高风险案件中建立了成功记录。该公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为客户服务。连续七年，Levi &amp; Korsinsky 在 ISS 证券集体诉讼服务的前 50 名报告中被评为美国顶级证券诉讼公司之一。律师广告。以往结果不保证类似结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>纽约，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

因证券违规行为，西氏医药服务公司（WST）被提起集体诉讼 - 请立即联系 Levi & Korsinsky